PT  - JOURNAL ARTICLE
AU  - Garcia, Maria A.
AU  - Barreras, Paula V.
AU  - Lewis, Allie
AU  - Pinilla, Gabriel
AU  - Sokoll, Lori J.
AU  - Kickler, Thomas
AU  - Mostafa, Heba
AU  - Caturegli, Mario
AU  - Moghekar, Abhay
AU  - Fitzgerald, Kathryn C.
AU  - ,
AU  - Pardo, Carlos A.
TI  - Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation
AID  - 10.1101/2021.01.10.20249014
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.10.20249014
4099  - http://medrxiv.org/content/early/2021/01/12/2021.01.10.20249014.short
4100  - http://medrxiv.org/content/early/2021/01/12/2021.01.10.20249014.full
AB  - BACKGROUND Neurological complications occur in COVID-19. We aimed to examine cerebrospinal fluid (CSF) of COVID-19 subjects with neurological complications and determine presence of neuroinflammatory changes implicated in pathogenesis.METHODS Cross-sectional study of CSF neuroinflammatory profiles from 18 COVID-19 subjects with neurological complications categorized by diagnosis (stroke, encephalopathy, headache) and illness severity (critical, severe, moderate, mild). COVID-19 CSF was compared with CSF from healthy, infectious and neuroinflammatory disorders and stroke controls (n=82). Cytokines (IL-6, TNFα, IFNγ, IL-10, IL-12p70, IL-17A), inflammation and coagulation markers (high-sensitivity-C Reactive Protein [hsCRP], ferritin, fibrinogen, D-dimer, Factor VIII) and neurofilament light chain (NF-L), were quantified. SARS-CoV2 RNA and SARS-CoV2 IgG and IgA antibodies in CSF were tested with RT-PCR and ELISA.RESULTS CSF from COVID-19 subjects showed a paucity of neuroinflammatory changes, absence of pleocytosis or specific increases in pro-inflammatory markers or cytokines (IL-6, ferritin, or D-dimer). Anti-SARS-CoV2 antibodies in CSF of COVID-19 subjects (77%) were observed despite no evidence of SARS-CoV2 viral RNA. A similar increase of pro-inflammatory cytokines (IL-6, TNFα, IL-12p70) and IL-10 in CSF of COVID-19 and non-COVID-19 stroke subjects was observed compared to controls. CSF-NF-L was elevated in subjects with stroke and critical COVID-19. CSF-hsCRP was present almost exclusively in COVID-19 cases.CONCLUSION The paucity of neuroinflammatory changes in CSF of COVID-19 subjects and lack of SARS-CoV2 RNA do not support the presumed neurovirulence of SARS-CoV2 or neuroinflammation in pathogenesis of neurological complications in COVID-19. Elevated CSF-NF-L indicates neuroaxonal injury in COVID-19 cases. The role of CSF SARS-CoV2 IgG antibodies is still undetermined.FUNDING This work was supported by NIH R01-NS110122 and The Bart McLean Fund for Neuroimmunology Research.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH R01-NS110122 and The Bart McLean Fund for Neuroimmunology Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Johns Hopkins Institutional Review Board (IRB) for longitudinal acquisition of clinical and biological samples in patients with neurological disorders. An informed consent was obtained from each patient or next-of-kin representative.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data will be made available to qualified investigators upon written request to the corresponding author.